Dr. Philip McMillan,  John McMillan

Two proline molecules. That is the whole trick.

Slot them into the spike protein of a coronavirus, right at the hinge where the S1 and S2 sections pull apart, and the protein stops flexing. On a structural diagram the change is almost invisible, two beads on a chain of more than a thousand. The immune system notices immediately.

That locked shape sits inside the Moderna vaccine, the Pfizer-BioNTech vaccine, the Johnson & Johnson adenovirus shot and the Novavax protein shot. It is also patented, co-owned by the National Institutes of Health with Dartmouth College and Scripps Research. Payments tied to it have run past a billion dollars.

Four hundred million from Moderna, under a licence signed in December 2022. Seven hundred and ninety-one and a half million from BioNTech. Individual federal inventors are normally capped at roughly $150,000 a year in royalty income. How much of the remainder reached the scientists who worked out the trick has never been made public.

Sit with the shape of that arrangement for a moment. The agency steering national vaccine policy held a stake in a patent sitting inside every major vaccine it was assessing.

A story that changed in four weeks

Senator Rand Paul has released 1,141 pages of diaries kept by Anthony Fauci across his tenure as NIAID director, covering December 2019 to December 2022. The material is vast, largely unexamined, and has drawn far more coverage for its celebrity anecdotes than for its virology.

The entries from the opening days carry the most weight.

On 31 January 2020, Fauci logged a phone call he described as far out. The participants believed the mutations around the furin cleavage site of the spike protein could not have arisen naturally, because the change demanded an evolutionary jump found nowhere in bat isolates.

The following day brought a conference call with virologists across the United States, Germany and beyond. The diary records: “there was not total agreement about the likelihood of deliberate insertion of the furin cleavage site. Ron Fouchier said he was sure this could occur naturally, and we should not waste our time and divert effort to pursue this.” Fauci noted the objection was predictable, given that Fouchier was the original gain-of-function researcher alongside Yoshihiro Kawaoka.

A furin cleavage site is not a footnote. SARS-family coronaviruses do not carry one. Its presence in SARS-CoV-2 is a genuine structural oddity, and in those first days the people best equipped to judge were openly arguing about whether it had been placed there.

Within a month, the proximal origin paper landed and argued for natural spillover. Raising a laboratory source became grounds for deplatforming.

What closes a four-week gap that wide?

Follow the money before the ideology

The straightforward reading requires no decades-long plan.

NIAID had been building coronavirus vaccines with Moderna since 2017, aimed at MERS. The stabilisation patent was already in hand. A pandemic driven by a novel coronavirus turned that patent into perhaps the most commercially significant piece of intellectual property in modern medicine.

Nobody anticipated a billion dollars. A hundred million would have been remarkable. By November 2020, with 90 percent efficacy announced and the phrase safe and effective saturating every broadcast, the position looked untouchable. The science had worked, the money was moving, and the reputational payoff was total.

Greed explains the behaviour more economically than any grand design. It usually does.

The version that would have won

The episode is painful for a specific reason. The vaccines had a defensible use case, and it was narrow.

The people at real risk of severe COVID were identifiable by early 2020: the elderly, the obese, those carrying significant comorbidities, those never previously infected. Vaccinate that group, cut severe disease and death, and let immunity build through infection across the low-risk majority.

“If they had only vaccinated the high-risk, and they had impacted on the severity of COVID, so less people died, the rest of the population got herd immunity, COVID would be over,” said Dr. Philip McMillan, the British physician and researcher who has tracked the immunology since 2020.

mRNA would have been remembered as the breakthrough of the century. Instead came mandates, extended to children and to pregnant women.

The biology was never in doubt

The case for universal vaccination rested on stopping transmission. That claim was in trouble from the start.

“The science always told you that an injectable vaccine could never effectively stimulate mucosal immunity,” said Dr. McMillan.

A shot into the deltoid produces circulating antibodies in the bloodstream. It does not reliably generate the secretory IgA that lines the nose, the throat and the gut, which is where a respiratory virus actually lands. That is why the vaccines could blunt severe disease without reliably interrupting spread, an effect that faded further as the virus drifted. The mandate rested on a biological claim the immunology did not support, and the immunology was known.

Private doubt, public certainty

The diaries show scientists inside the process asking the same questions being labelled misinformation outside it.

Page 882 captures the wrangling over booster authorisation: strife within the FDA producing what the diary calls a completely confusing authorisation, and Rochelle Walensky facing an ACIP unwilling to recommend the shots for people under thirty or forty. The entry ends: “What a mess. Let us see if in the long run we can make some lemonade out of these lemons.”

On boosters themselves, Fauci recorded a good conversation with Paul Offit, who felt they may have jumped the gun, before concluding that “the boosters are safe and to put it in plain terms, it can help and it certainly cannot hurt.”

Read that sentence twice. It hedges the benefit and asserts the safety absolutely. No trial had established the second half.

And when Israel began requiring boosters within six months of vaccinating most of its population, that was a signal about durability. It deserved a pause rather than an acceleration.

Page 856 records an August 2021 conversation with Gabon’s health minister about vaccine hesitancy. Third doses were being planned in wealthy countries at a moment when much of Africa had almost no supply. The continent reached population immunity through infection instead. That outcome has never been properly reckoned with.

The lock that may not open

The prefusion stabilisation raises a question that has gone largely unexamined.

Locking the spike made it a better immunogen by preventing it from changing shape. Whether the same lock also makes the protein harder for the body to break down and clear is unresolved. A subset of patients appear to carry circulating spike fragments long after exposure, and those fragments have been linked to persistent vascular, neurological and immune symptoms. If a locked conformation resists normal clearance in some people, the design choice that improved the immune response would carry a long tail of harm.

That question exists only because the rollout went wide. Had it stayed with the high-risk cohort, the signal would have been too small to see.

What to do with 1,141 pages

Nobody reading this can compel a hearing or subpoena a royalty ledger. What readers can do is treat their own health as a live question rather than a settled one.

Ask what was in the shot. Ask what is known about spike persistence and what is merely assumed. Ask a clinician for the evidence behind a recommendation rather than the summary of it.

The diaries make one thing plain. The scientific community held its doubts privately while presenting certainty publicly. That gap closes only when enough people ask questions that cannot be waved away.

Called before the Senate Homeland Security Committee on 29 July, Fauci invoked the Fifth Amendment more than a hundred times and answered almost nothing. His lawyers said the risk of a perjury prosecution left him no choice. Whatever that silence means legally, it leaves a great many questions standing.